Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

VENTANA PD-L1 (SP142), a complimentary diagnostic immunohistochemistry (IHC) assay to ascertain tumor PD-L1 status for patients with metastatic urothelial cancer considering treatment with atezolizuma

Funder: National Cancer Institute

Funding period
USD 100 K
Funding amount
Abstract
Abstract NCI Protocol: NRG-GY017 ?Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer.? Briefly, PD-L1 expression will be assessed using the rabbit anti-human PD-L1 antibody (clone SP142). Using IHC, PD-L1 expression will be scored in tumor cells (as percentage of PD-L1-expressing tumor cells: TC3?50%, TC2?5% and <50%, TC1?1% and <5%, and TC0<1%) and tumor infiltrating immune cells (as percentage of tumor area: IC3?10%, IC2?5% and <10%, IC1?1% and <5%, and IC0<1%). To satisfy the primary objective of the study, the following will be assessed in response to sequential versus concurrent atezolizumab and radiation: (1) peripheral blood T Cell Receptor (TCR) clonality, and (2) peripheral blood expansion of TCR clones, including TCR clones identified in tumor samples. For assessment of the primary endpoint, pre-treatment FFPE tumor biopsies (to determine which TCR clones are present within the tumor), as well as pre-treatment and on-treatment bloods will be required.
Similar projects All >
Sorted by: Start Date
Project list item
Defining the impact of intra-tumoral morphologic, immune and mutational heterogeneity in urothelial carcinoma

National Cancer Institute to HIKMAT AL-AHMADIE

USD 821,670
2019 - 2024
Project list item
Modulation of regulatory T cells in the bladder tumor environment by anti-PD-L1 immunotherapy

Bladder Cancer Advocacy Network to David Yoonsuk Oh, Lawrence Fong

USD 50,000
2018 - 2019
Project list item
Overcoming Urothelial Cancer Atezolizumab Resistance by Epigenetic Therapy

American Association For Cancer Research to Peter Jones, Hui Shen, Jaroslav Jelinek, Scott Jewell, Stephen B. Baylin, Peter Jones, Kerry Campbell, Patrick Gavin, Elizabeth Plimack, Jean-Pierre Issa

 
-

System

Categories
  • FOR (ANZSRC)

    1107 Immunology

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science